Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dominoes falling… obviously the MHRA is working closely with mgmt
More lies re: post-hoc
This week or so? Based on what?
Please link to her using pfs as primary in that trial
This might be your dumbest narrative yet
In high school my daughter was voted most likely to conceive!
if constant crying helped, we'd be at $1,000 per share by now!
Relatively few tumors of any type are MMR deficient/ MSI high etc. Not a huge competitor at all- and CIs like this, keytruda et al will likely play well together with DCVAX.
Added shares!!!
What things has he been right about? I must have missed them
all this and COMMUNICATION WITH THE GD SHAREHOLDERS
possibly, but I wouldn't bank on it. In general it comes down to the mutator status of the particular tumor type, i.e. MSI (sometimes called MSI-high) tumors are highly mutated so they respond well to immune-based therapies like PD1 and PD(L)1 antibodies (keytruda, dostarlimab etc) and presumably to something like DCVAX added on top. This is also why these classes of drugs work so well in melanoma and in smoking-associated lung cancers etc (high number of mutations). For other (non-MSI) colon cancers, they aren't typically served very well by I/O agents so far from what I have seen (?).
Obviously this has the caveat that adding a DC educator like DCVAX to the antibodies could have profound effects and improve the performance in non-MSI tumors- but I would have to see the data first.
All that said, ppl who think PD1 directed agents are a threat to DC-VAX-L aren't very educated about the biology and history of trials IMO.
I was there and actually felt bad for him, he was haggard, fat and dressed like a slob with white trash tattoos while everyone else was dressed nicely and upbeat. He wore a mask and wasn’t looking at the slides for the most part when I checked on him. He’s a toothless tiger and I kind of pity him now having seen it.
Also in response to questions there were about 190 chairs. I’d say 80-90% full but also some people standing in the back during the talk
To the negative fudders I would at least wait until the audio portion of the talk comes out— Bosch and Murthy were saying much more than what was on the slides
AF is in the industry theater sitting in the back row. Didn’t know he has trashy tattoos ??.
Actually if you guys want me to ask some questions at the booth, give me a list-
I'm not sure who will be manning the booth tomorrow but I plan to ask some ?s about quiet period, next steps etc. Hopefully we will get a PR today anyway but...
I attend ASCO every year, and I really doubt anyone is closely policing or even paying attention to these types of minutia. I've worked for companies who have done IETs at ASCO as well. Just IMO.
I still think (hope?) they wouldn’t have done the NYAS thing if a pub wasn’t pretty damn close. Ugh.
I’ll be there and plan to record as much as I can (if they allow it)- hopefully the audio will be good so I can transcribe it later
If AF shows up at industry theater at ASCO, I’ve decided to film him the entire time with my phone. I also plan to ask him about his false claims on camera, as well as his father’s criminal charges for stealing from employees. Should be fun!
This is just getting sad
Brian who?
Curious if you’re still pretending to be a long, or if you dropped the thin façade. :)
agreed- I feel better than I have in months!
This conference seems like amateur hour the way they are running things
Actually if they announced acceptance of the ECA by an RA(s) I could see that being very positive even if they didn’t show the TLD.
Could we see a pub or PR today? What are your thoughts
Where did you get the list??
Wasted? Learning is rewarding- you should try it!
How’s your short position?
Acceleron, Merck 11.5B
First day?
https://www.fiercepharma.com/special-report/top-10-biopharma-m-a-deals-2021
Here are more examples to cure your ignorance. :)
The Merck comment says nothing about vaccines…
Most monoclonal antibodies are being formulated for subQ administration these days
Why would subQ keytruda have anything to do with a deal for NWBO?
A stretch to associate that with DCVAX at this point, IMO
That's the dumbest take I've seen in quite a while here- congrats!
Agreed!
Awesome! Thank you
Why did you lie about journals not coordinating publication with presentations?
https://ascopubs.org/op/asco-2022-simultaneous-publication